IL6 and cancer: As shown in Figure 3E-F, the levels of inflammatory cytokines (human IL-2 and IFN-γ) in the animals dosed with Her2/VEGFR2/CD3 (SO) were higher than those in the animals that received the other drugs, but no detectable human or murine IL-6 was observed in these mice (Figure S26), suggesting that the tsAb could efficiently induce tumor-redirected T-cell activation, but was potentially safe in avoiding cytokine storm syndrome in cancer patients.